. 2017 Nov 10;17:747. doi: 10.1186/s12885-017-3719-1

Table 2.

Results from CPRD (time-varying and non-time-varying covariate analysis by adjustment)

Time-Varying (follow-up from cancer diagnosis)
				Unadjusted			Adjusted for age			Multivariate Model^a
		No. of patients	No. Died	HR	95% CI		HR	95% CI		HR	95% CI
All patients	No VTE	12,591	3504	1			1			1
All patients	VTE	611	298	2.97	2.62	3.36	2.58	2.27	2.92	2.42	2.13	2.75
Local disease	No VTE	4823	726	1			1			1
Local disease	VTE	214	81	4.05	3.17	5.16	3.21	2.51	4.1	2.94	2.29	3.77
Regional disease	No VTE	2800	798	1			1			1
Regional disease	VTE	161	89	3.23	2.57	4.05	2.9	2.31	3.64	2.53	2.01	3.19
Distant metastases	No VTE	449	300	1			1			1
Distant metastases	VTE	21	14	1.4	0.8	2.47	1.27	0.72	2.24	1.47	0.82	2.63
Unknown stage	No VTE	4519	1680	1			1			1
Unknown stage	VTE	215	114	2.45	2	3.01	2.27	1.85	2.78	2.33	1.89	2.87
Non-time-varying (follow-up commencing 6 months after cancer diagnosis)
All patients	No VTE	12,148	3171	1			1			1
All patients	VTE	138	54	1.63	1.24	2.14	1.50	1.15	1.96	1.22	0.93	1.60
Local disease	No VTE	4854	743	1			1			1
Local disease	VTE	45	11	1.72	0.95	3.12	1.51	0.83	2.74	1.25	0.68	2.27
Regional disease	No VTE	2834	834	1			1			1
Regional disease	VTE	46	22	1.73	1.13	2.64	1.53	1	2.34	1.17	0.76	1.79
Distant metastases	No VTE	331	212	1			1			1
Distant metastases	VTE	5	3	1.34	0.43	4.18	1.37	0.44	4.3	1.32	0.40	4.35
Unknown stage	No VTE	4129	1382	1			1			1
Unknown stage	VTE	42	18	1.37	0.86	2.18	1.34	0.84	2.14	1.23	0.77	1.96

^aage plus: stage (where not stratified), grade, comorbidity, tamoxifen therapy, smoking, body mass index, surgery and chemotherapy. In the time-varying analysis, no. died represents the number of deaths in women who never developed VTE